慢性髓系恶性肿瘤异基因造血细胞移植中甲氨蝶呤与麦考酚酯预防方案的比较:欧洲血液与骨髓移植学会慢性恶性肿瘤工作组的一项回顾性分析
该回顾性EBMT登记研究纳入2007至2017年间接受异基因造血细胞移植的13699例慢性髓系恶性肿瘤及继发性急性髓系白血病患者,比较钙调神经磷酸酶抑制剂联合甲氨蝶呤或麦考酚酯预防移植物抗宿主病的结局差异。甲氨蝶呤组全因死亡风险(HR 0.87)和非复发死亡风险(HR 0.86)低于麦考酚酯组,而复发风险与无复发生存无显著差异;甲氨蝶呤组2-4级急性GVHD风险及急性GVHD后死亡风险降低。
要点
- 甲氨蝶呤联合钙调神经磷酸酶抑制剂组全因死亡风险低于麦考酚酯组(HR 0.87)。
- 甲氨蝶呤组非复发死亡风险低于麦考酚酯组(HR 0.86)。
- 两组复发风险与无复发生存无显著差异;甲氨蝶呤组2-4级急性GVHD风险及急性GVHD后死亡风险降低。
核心结论
- 在慢性髓系恶性肿瘤及继发性急性髓系白血病异基因造血细胞移植中,甲氨蝶呤联合钙调神经磷酸酶抑制剂预防方案与更优的生存相关,且急性GVHD后生存更优。
研究设计与样本
- 该研究为EBMT登记数据库的回顾性研究,纳入2007至2017年间接受异基因造血细胞移植、使用甲氨蝶呤或麦考酚酯联合钙调神经磷酸酶抑制剂预防的患者,共13699例,来自321个中心,中位随访42.8个月(IQR 19.8-74.5个月)。
主要发现
- 在全队列多变量Cox回归模型中,甲氨蝶呤组全因死亡风险低于麦考酚酯组(HR 0.87,95% CI 0.81-0.95,p=0.001),非复发死亡风险低于麦考酚酯组(HR 0.86,95% CI 0.78-0.96,p=0.006),预防方案与亚组间无显著交互作用。
- 甲氨蝶呤组与麦考酚酯组复发风险无显著差异(HR 1.03,95% CI 0.94-1.14,p=0.53),无复发生存无显著差异(HR 0.95,95% CI 0.88-1.01,p=0.12)。
- 甲氨蝶呤组2-4级急性GVHD风险降低,急性GVHD后死亡风险降低;在移植后3个月无急性GVHD患者的landmark分析中,预防方案与结局无关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) frequently encompass a combination of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF). The aim of this retrospective, EBMT registry-based study was to determine outcome differences for chronic myeloid malignancies and secondary acute myeloid leukemia (sAML) between MTX- and MMF-based prophylaxis regimens while taking potential heterogeneity between subgroups into consideration. Eligible were patients transplanted between 2007 and 2017 who received either MTX- or MMF prophylaxis in combination with a CNI. Endpoints after allo-HCT were overall survival, relapse-free survival (RFS), relapse incidence, non-relapse mortality (NRM), and Grades 2-4 acute GVHD (aGvHD). Overall, 13 699 patients from 321 centers were included. Median follow-up was 42.8 months (IQR 19.8-74.5 months). MTX prophylaxis was associated with reduced overall mortality (HR 0.87, 95% CI 0.81-0.95, p = 0.001) and NRM (HR 0.86, 95% CI 0.78-0.96, p = 0.006) compared with MMF in multivariable Cox regression models in the whole cohort without significant interaction between prophylaxis and subgroups. In contrast, there was no significant association of prophylaxis with risk of relapse (HR 1.03 MTX vs. MMF, 95% CI 0.94-1.14, p = 0.53) or RFS (HR 0.95, 95% CI 0.88-1.01, p = 0.12). There was a reduced risk of Grades 2-4 acute GVHD and reduced mortality after acute GVHD with MTX prophylaxis but no association with outcome in a landmark analysis in patients without aGvHD at 3 months after allo-HCT. In conclusion, MTX-complemented CNI prophylaxis was associated with favorable survival, and with favorable survival after aGVHD compared with MMF.
引用
- Luft T, Gras L, Koster L, et al. Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2024. PMID: 39605194. doi:10.1002/ajh.27531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。